Abstract
Pharmacogenetic approach to antidepressant (AD) response is a promising avenue toward individualizing AD treatment. This is particularly relevant in pediatric populations because of concerns about the suicide risk of serotonin selective reuptake inhibitors (SSRIs), resulting in a black-box warning. However, to date, no specific gene or polymorphism has been consistently implicated as a marker of AD side effect (SE) in the pediatric population. The aim of this study was to examine the association between polymorphisms in genes related to the serotonergic system and citalopram SE’s in children and adolescents with major depressive disorder (MDD)/dysthymia and/or anxiety disorders. Outpatients (N = 87, 44 % males), aged 7–18 years with a DSM-IV-TR diagnosis of MDD/dysthymia and/or an anxiety disorder were treated in an 8-week open trial with 20–40 mg/day of citalopram. SE’s were rated using a questionnaire devised specifically for this study. Association analysis between known/candidate genetic variants in three genes (5-HTR2A, 5-HTR1Dβ, 5-HTR2C) and SE’s was conducted. Agitation was more common in boys than girls (male:female 42.1 vs. 18.7 %, χ 2 = 5.61, df = 1, p = 0.018). Subjects with 5-HTR1Dβ CC genotype showed more agitation vs. both CG and GG genotypes (CC:CG:GG 71.4 vs. 33.3 vs. 18.1 %, χ 2 = 8.99, df = 2, p = 0.011). The 5-HTR1Dβ CC genotype was associated with more reports of agitation. It has been suggested that agitation may be an intermediate phenotype to suicidal behavior. Thus, it seems that 5-HTR1Dβ polymorphism may be involved in citalopram-related agitation in children and adolescents treated for depression and/or anxiety.
Similar content being viewed by others
References
Adegbite-Adeniyi C, Gron B, Rowles BM, Demeter CA, Findling RL (2012) An update on antidepressant use and suicidality in pediatric depression. Expert Opin Pharmacother 13(15):2119–2130
Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG (2015) Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharmacogenom J 15(5):443–451
Amitai M, Chen A, Weizmann A, Apter A (2015) SSRI-induced activation syndrome in children and adolescents—what is next? Curr Treat Options Psychiatry 2(1):28–37
Bernstein GA, Shaw K (1997) Practice parameters for the assessment and treatment of children and adolescents with anxiety disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 36(10 Suppl):69S–84S
Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, Neer SM (1997) The screen for child anxiety related emotional disorders (SCARED): scale construction and psychometric characteristics. J Am Acad Child Adolesc Psychiatry 36:545–553
Birmaher B, Brent DA, Benson RS (1998) Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry 37(11):1234–1238
Birmaher B, Brent DA, Chiappetta L, Bridge J, Monga S, Baugher M (1999) Psychometric properties of the screen for child anxiety related emotional disorders (SCARED): a replication study. J Am Acad Child Adolesc Psychiatry 38:1230–1236
Blazquez A, Mas S, Plana MT, Lafuente A, Lázaro L (2012) Fluoxetine pharmacogenetics in child and adult populations. Eur Child Adolesc Psychiatry 21:599–610
Brent DA, Bridge J, Johnson BA, Connolly J (1996) Suicidal behavior runs in families. A controlled family study of adolescent suicide victims. Arch Gen Psychiatry 53(12):1145–1152
Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, Ren L, Brent DA (2007) Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 297(15):1683–1696
Brummett BH, Babyak MA, Jiang J, Shah SH, Becker RC, Haynes C, Chryst-Ladd M, Craig DM, Hauser ER, Siegler IC, Kuhn CM, Singh A, Williams RB (2013) A functional polymorphism in the 5HTR2C gene associated with stress responses also predicts incident cardiovascular events. PLoS One 8(12):1–7
Cheung AH, Dewa CS, Levitt AJ (2005) Clinical review of mania, hostility and suicide-related events in children and adolescents treated with antidepressants. Paediatr Child Health 10(8):457–463
Clark SL, Adkins DE, Aberg K, Hettema JM, McClay JL, Souza RP, van den Oord EJCG (2012) Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D. Psychol Med 42:1151–1162
Gibbons RD, Brown CH, Hur K, Davis J, Mann JJ (2012) Suicidal thoughts and behavior with antidepressant treatment: reanalysis of the randomized placebo-controlled studies of fluoxetine and venlafaxine. Arch Gen Psychiatry 69(6):580–587
Guy W (1976) Clinical global improvement scale. Assessment manual of psychopharmacology. National Institute of Mental Health, Rockville (Maryland)
Hammad TA, Laughren T, Racoosin J (2006) Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 63(3):332–339
Hofer P, Schosser A, Calati R, Serretti A, Massat I, Kocabas NA, Konstantinidis A, Mendlewicz J, Souery D, Zohar J, Juven-Wetzler A, Montgomery S, Kasper S (2016) The impact of serotonin receptor 1A and 2A gene polymorphisms and interactions on suicide attempt and suicide risk in depressed patients with insufficient response to treatment—a European multicentre study. Int Clin Psychopharmacol 31(1):1–7. doi:10.1097/YIC.0000000000000101
Johnson JG, Cohen P, Skodol AE, Oldham JM, Kasen S, Brook JS (1999) Personality disorders in adolescence and risk of major mental disorders and suicidality during adulthood. Arch Gen Psychiatry 56(9):805–811
Kato M, Serretti A (2010) Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 15(5):473–500
Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980–988
Kim CD, Seguin M, Therrien N, Riopel G, Chawky N, Lesage AD, Turecki G (2005) Familial aggregation of suicidal behavior: a family study of male suicide completers from the general population. Am J Psychiatry 162(5):1017–1019
Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, Roots I, Brockmöller J (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9(5):442–473
Kronenberg S, Apter A, Brent DA, Schirman S, Melhem N, Pick N, Gothelf D, Carmel M, Frisch A, Weizman A (2007) Serotonin transporter polymorphism (5-HTTLPR) and citalopram effectiveness and side effects in children with depression and/or anxiety disorders. J Child Adolesc Psychopharmacol 17(6):741–750
Lappalainen J, Dean M, Charbonneau L, Virkkunen M, Linnoila M, Goldman D (1995a) Mapping of the serotonin 5-HT1D beta autoreceptor gene on chromosome 6 and direct analysis for sequence variants. Am J Med Genet 60(2):157–161
Lappalainen J, Zhang L, Dean M, Oz M, Ozaki N, Yu DH, Virkkunen M, Weight F, Linnoila M, Goldman D (1995b) Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C). Genomics 27(2):274–279
Lohoff FW, Ferraro TN (2010) Pharmacogenetic considerations in the treatment of psychiatric disorders. Expert Opin Pharmacother 11(3):423–439
Maddox JC, Levi M, Thompson C (1994) The compliance with antidepressants in general practice. J Psychopharmacol 8(1):48–52
Mundo E, Zai G, Lee L, Parikh SV, Kennedy JL (2001) The 5HT1Dbeta receptor gene in bipolar disorder: a family-based association study. Neuropsychopharmacology 25(4):608–613
Murphy GM, Kremer C, Rodrigues HE, Schatzberg AF (2003) Pharmacogenetics of antidepressant medication intolerance. Am J Pschicatry 160:1830–1835
Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L (2006) Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314:1930–1933
Papakostas GI (2009) Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 70(Suppl 6):16–25
Popova NK (2006) From genes to aggressive behavior: the role of serotonergic system. BioEssays 28(5):495–503
Poznanski E, Freeman LN, Mokros HB (1985) Children’s depression rating scale-revised. Psychopharmacol Bull 21:979–989
Qin B, Zhang Y, Zhou X, Cheng P, Liu Y, Chen J, Fu Y, Luo Q, Xie P (2014) Selective serotonin reuptake inhibitors versus tricyclic antidepressants in young patients: a meta-analysis of efficacy and acceptability. Clin Ther 36(7):1087–1095
Rotberg B, Kronenberg S, Carmel M, Frisch A, Brent D, Zalsman G, Apter A, Weizman A (2013) Additive effects of 5-HTTLPR (serotonin transporter) and tryptophan hydroxylase 2 G-703T gene polymorphisms on the clinical response to citalopram among children and adolescents with depression and anxiety disorders. J Child Adolesc Psychopharmacol 23(2):117–122
Schirman S, Kronenberg S, Apter A, Brent DA, Melhem N, Pick N, Carmel M, Frisch A, Weizman A, Gothelf D (2010) Effectiveness and tolerability of citalopram for the treatment of depression and anxiety disorders in children and adolescents: an open-label study. J Neural Transm 117:139–145
Seroczynski AD, Bergeman CS, Coccaro EF (1999) Etiology of the impulsivity/aggression relationship: genes or environment? Psychiatry Res 86(1):41–57
Serretti A, Artioli P (2004) The pharmacogenomics of selective serotonin reuptake inhibitors. Pharmacogenomics J 4(4):233–244
Shanee N, Apter A, Weizman A (1997) Psychometric properties of the K-SADS-PL in an Israeli adolescent clinical population. Isr J Psychiatry Relat Sci 34:179–186
Souery D, Oswald P, Massat I, Bailer U, Bollen J, Demyttenaere K, Kasper S, Lecrubier Y, Montgomery S, Serretti A, Zohar J, Mendlewicz J (2007) Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 68(7):1062–1070
Strawn JR, Adler CM, McNamara RK, Welge JA, Bitter SM, Mills NP, Barzman DH, Cerullo MA, Chang KD, Strakowski SM, DelBello MP (2014) Antidepressant tolerability in anxious and depressed youth at high risk for bipolar disorder: a prospective naturalistic treatment study. Bipolar Disord 16(5):523–530
Strawn JR, Welge JA, Wehry AM, Keeshin B, Rynn MA (2015) Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis. Depress Anxiety 32(3):149–157
Van Praag HM (2000) Serotonin disturbances and suicide risk: is aggression or anxiety the interjacent link? Crisis 21(4):160–162
Warren JT, Peacock ML, Rodriguez LC, Fink JK (1993) An MspI polymorphism in the hyman serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis. Hum Mol Genet 2(3):338
Zouk H, McGirr A, Lebel V, Benkelfat C, Rouleau G, Turecki G (2007) The effect of Genetic variation of the serotonin 1B receptor gene on impulsive aggressive behavior and suicide. Am J Med Genet B Neuropsychiatr Genet 144B(8):996–1002
Author information
Authors and Affiliations
Corresponding author
Additional information
M. Amitai and S. Kronenberg equally contributed to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Amitai, M., Kronenberg, S., Carmel, M. et al. Pharmacogenetics of citalopram-related side effects in children with depression and/or anxiety disorders. J Neural Transm 123, 1347–1354 (2016). https://doi.org/10.1007/s00702-016-1585-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-016-1585-7